focus -WSS

focus

author：entertainment 2025-09-29 21:28:02 - browse：187

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Global childhood vaccinations edge closer to pre

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Mike Pence clashes with Tucker Carlson in Iowa

Involuntary treatment for addiction doesn't work

Think you might have Covid

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

leisure time

focus

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Congress: Eradicate hepatitis C and reduce the deficit

How one medical school became remarkably diverse

How digital therapeutics firms are pivoting after Pear's bankruptcy

Virginia high school admissions case could be legal follow

Elizabeth Holmes banned from government health programs

United colonoscopy coverage change 'may cost lives,' doctors say

New brain studies show LSD's effects on the brain in full color

New air purifier tech could be key to improving indoor air quality

Everything to know for the next Powerball drawing as jackpot hits $1 billion

focus

The surgeon had a dilemma only a Nazi medical text could resolve

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Why police arrested suspected Gilgo Beach killer away from his house

My yearlong odyssey to get my son’s ADHD medication covered

J&J expands global access to TB drug amid advocacy campaign

AI generated plenty of interest at JPM but not a lot of trust

focus

Wikipedia

explore

hotspot